---
document_datetime: 2023-09-21 20:50:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ibrance-epar-all-authorised-presentations_en.pdf
document_name: ibrance-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 2.470523
conversion_datetime: 2025-12-15 20:49:54.816624
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging                          | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|----------------------------------------------|-------------|
| EU/1/16/1147/001 | IBRANCE           | 75 mg      | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/PVC/alu)                  | 21 capsules |
| EU/1/16/1147/002 | IBRANCE           | 75 mg      | Capsule, hard         | Oral use                  | bottle (HDPE)                                | 21 capsules |
| EU/1/16/1147/003 | IBRANCE           | 100 mg     | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/PVC/alu)                  | 21 capsules |
| EU/1/16/1147/004 | IBRANCE           | 100 mg     | Capsule, hard         | Oral use                  | bottle (HDPE)                                | 21 capsules |
| EU/1/16/1147/005 | IBRANCE           | 125 mg     | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/PVC/alu)                  | 21 capsules |
| EU/1/16/1147/006 | IBRANCE           | 125 mg     | Capsule, hard         | Oral use                  | bottle (HDPE)                                | 21 capsules |
| EU/1/16/1147/007 | IBRANCE           | 75 mg      | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/PVC/alu)                  | 63 capsules |
| EU/1/16/1147/008 | IBRANCE           | 100 mg     | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/PVC/alu)                  | 63 capsules |
| EU/1/16/1147/009 | IBRANCE           | 125 mg     | Capsule, hard         | Oral use                  | blister (PVC/PCTFE/PVC/alu)                  | 63 capsules |
| EU/1/16/1147/010 | IBRANCE           | 75 mg      | Film-coated tablet    | Oral use                  | blister (PVC/OPA/alu/PVC/alu)                | 21 tablets  |
| EU/1/16/1147/011 | IBRANCE           | 75 mg      | Film-coated tablet    | Oral use                  | blister (PVC/OPA/alu/PVC/alu)                | 63 tablets  |
| EU/1/16/1147/012 | IBRANCE           | 100 mg     | Film-coated tablet    | Oral use                  | blister (PVC/OPA/alu/PVC/alu)                | 21 tablets  |
| EU/1/16/1147/013 | IBRANCE           | 100 mg     | Film-coated tablet    | Oral use                  | blister (PVC/OPA/alu/PVC/alu)                | 63 tablets  |
| EU/1/16/1147/014 | IBRANCE           | 125 mg     | Film-coated tablet    | Oral use                  | blister (PVC/OPA/alu/PVC/alu)                | 21 tablets  |
| EU/1/16/1147/015 | IBRANCE           | 125 mg     | Film-coated tablet    | Oral use                  | blister (PVC/OPA/alu/PVC/alu)                | 63 tablets  |
| EU/1/16/1147/016 | IBRANCE           | 75 mg      | Film-coated tablet    | Oral use                  | blister (PVC/OPA/Al/PVC/Al) in wallet carton | 21 tablets  |
| EU/1/16/1147/017 | IBRANCE           | 100 mg     | Film-coated tablet    | Oral use                  | blister (PVC/OPA/Al/PVC/Al) in wallet carton | 21 tablets  |
| EU/1/16/1147/018 | IBRANCE           | 125 mg     | Film-coated tablet    | Oral use                  | blister (PVC/OPA/Al/PVC/Al) in wallet carton | 21 tablets  |